View Filing Data

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2018	May 12, 2018
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		11,804,073
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and Cash Equivalents	$ 2,232,803	$ 766,189
Certificates of Deposit		244,971
Accounts Receivable	241,764	137,499
Notes Receivable	167,512	667,512
Inventories	272,556	265,045
Prepaid Expense and other assets	208,305	289,966
Total Current Assets	3,122,940	2,371,182
Notes Receivable	1,112,524	1,070,000
Investment in Subsidiary	1,542,250
Fixed Assets, net	106,009	87,716
Intangibles, net	115,714	95,356
Total Assets	5,999,437	3,624,254
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	186,309	140,462
Accrued Expenses	558,439	785,215
Deferred Revenue	38,856	6,663
Total Liabilities	783,604	932,340
Commitments and Contingencies
Stockholders’ Equity:
Common Stock, $.01 par value, 50,000,000 authorized, 11,804,073 and 6,943,283 outstanding	118,040	69,432
Additional paid-in capital	(61,622,067)	(57,380,256)
Accumulated Deficit	56,525,066	54,765,045
Total Stockholders' Equity	5,215,833	2,691,914
Total Liabilities and Stockholders' Equity	5,999,437	3,624,254
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock	792	792
Series C Convertible Preferred Stock [Member]
Stockholders’ Equity:
Convertible Preferred Stock		$ 6,479

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares outstanding (in shares)	11,804,073	6,943,283
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	0	647,819

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue	$ 411,593	$ 175,166
Cost of goods sold	117,343	36,992
Gross margin	294,250	138,174
General and administrative expense	1,216,144	1,132,073
Operations expense	287,590	200,494
Sales and marketing expense	550,538	147,454
Total Expense	2,054,272	1,480,021
Net loss attributable to common shareholders	(1,760,022)	(1,341,847)
Comprehensive loss	$ (1,760,022)	$ (1,341,847)
Loss per common share - basic and diluted (in dollars per share)	$ (0.15)	$ (0.21)
Weighted average shares used in computation - basic and diluted (in shares)	11,383,217	6,450,967

Statement of Stockholders' Equity (Unaudited) - USD ($)	Over-Allotment Option [Member] Common Stock [Member]	Over-Allotment Option [Member] Additional Paid-in Capital [Member]	Over-Allotment Option [Member] Retained Earnings [Member]	Over-Allotment Option [Member]	Consulting Agreement One [Member] Common Stock [Member]	Consulting Agreement One [Member] Additional Paid-in Capital [Member]	Consulting Agreement One [Member]	Consulting Agreement Two [Member] Common Stock [Member]	Consulting Agreement Two [Member] Additional Paid-in Capital [Member]	Consulting Agreement Two [Member]	Private Placement [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member]	Helomics Holding Corp. [Member] Common Stock [Member]	Helomics Holding Corp. [Member] Additional Paid-in Capital [Member]	Helomics Holding Corp. [Member]	Investor Relations Consultant [Member] Common Stock [Member]	Investor Relations Consultant [Member] Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2016																										4,564,428
Balance at Dec. 31, 2016																									$ 792	$ 45,644	$ 47,894,196	$ (47,018,451)	$ 1,501	$ 923,682
Shares issued pursuant to the public offering, net (in shares)	175,000										1,213,819															1,750,000
Shares issued pursuant to the public offering, net	$ 1,750	$ 392,000		$ 393,750								$ 12,138	$ 1,201,681	$ 1,213,819												$ 17,500	3,403,688			3,421,188
Vesting Expense																											4,042,256			4,042,256
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares)																										(400,000)
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement																										$ (4,000)				(4,000)
Shares issued for services (in shares)					100,000			43,333										50,000
Shares issued for services					$ 1,000	$ 219,000	$ 220,000	$ 433	$ 63,699	$ 64,132								$ 500	$ 78,500	$ 79,000
Unrealized (loss) from marketable securities																												(1)	(1,501)	(1,501)
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																								(566,000)		660,522
Preferred conversion to common shares pursuant to a private placement agreement																									(5,659)	$ 6,604	85,236			86,182
Net loss																												(7,746,593)		(7,746,593)
Balance (in shares) at Dec. 31, 2017																								(647,819)		(6,943,283)
Balance at Dec. 31, 2017																									7,271	$ 69,432	57,380,256	(54,765,045)		2,691,914
Shares issued pursuant to the public offering, net (in shares)	215,247																									2,900,000
Shares issued pursuant to the public offering, net	$ 2,153	$ 202,268	$ 1	$ 204,422																						$ 29,000	2,726,087			2,755,087
Vesting Expense																											226,387			226,387
Unrealized (loss) from marketable securities
Preferred conversion to common shares pursuant to a private placement agreement (in shares)																								(647,819)		589,747
Preferred conversion to common shares pursuant to a private placement agreement																									(6,479)	$ 5,897	582
Net loss																												(1,760,022)		(1,760,022)
Investment in subsidiary pursuant to Helomics 20% acquisition (in shares)															1,100,000
Investment in subsidiary pursuant to Helomics 20% acquisition															$ 11,000	$ 1,031,250	$ 1,042,250
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share (in shares)																					55,796
E warrant exercises pursuant to S-3 public offering at $1.00 exercise price per share																					$ 558	$ 55,238	$ 55,796
Balance (in shares) at Mar. 31, 2018																										(11,804,073)
Balance at Mar. 31, 2018																									$ 792	$ 118,040	$ 61,622,067	$ (56,525,066)		$ 5,215,833

Statement of Stockholders' Equity (Unaudited) (Parentheticals)	Dec. 31, 2017 $ / shares
Investor Relations Consultant [Member]
Price of shares issued (in dollars per share)	$ 1.58
Shares Issued, Price Per Share	$ 1.58

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flow from operating activities:
Net loss	$ (1,760,022)	$ (1,341,847)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	18,167	18,574
Vested stock options and warrants	226,387	587,444
Loss from sale of marketable securities		(1,837)
Changes in assets and liabilities:
Accounts receivable	(104,265)	(29,587)
Inventories	(7,511)	23,022
Prepaid expense and other assets	81,661	(11,645)
Accounts payable	45,847	(140,848)
Accrued expenses	(226,775)	(265,893)
Deferred Revenue	32,193	6,409
Net cash used in operating activities:	(1,694,318)	(1,156,208)
Cash flow from investing activities:
Proceeds from sale of marketable securities		284,665
Purchase of certificates of deposit		(2,593,985)
Redemption of certificates of deposit	244,971
Advance on notes receivable	(42,524)
Purchase of fixed assets	(32,789)	(26,898)
Purchase of intangibles	(24,029)	(194)
Net cash provided by (used in) investing activities:	145,629	(2,336,412)
Cash flow from financing activities:
Proceeds from exercise of warrants into common stock	55,794
Issuance of common stock	2,959,509	3,814,938
Net cash provided by (used in) financing activities	3,015,303	3,814,938
Net increase in cash and cash equivalents	1,466,614	322,318
Cash at beginning of period	766,189	1,764,090
Cash at end of period	2,232,803	2,086,408
Non-cash transactions:
Conversion of Preferred Stock to Common Stock	6,479
Investment in Subsidiary	$ 1,542,250

Note 1 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE

— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

the Company filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name from Skyline Medical Inc. to Precision Therapeutics Inc., effective

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

March 31, 2018,

the Company had

11,804,073

shares of common stock outstanding, par value

$.01

per share. The Company is a healthcare products and services company that is expanding its business to take advantage of emerging areas of the dynamic healthcare market. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of proprietary cleaning fluid and filters to users of its systems.

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products. The Company has acquired

25%

of the capital stock of Helomics Holding Corporation (“Helomics”), a pioneering Contract Research Organization (“CRO”) services company, and the Company has announced that it has a letter of intent for a proposed merger transaction to acquire the remaining ownership of Helomics. In addition, the Company has formed a wholly-owned subsidiary, TumorGenesis Inc., to develop the next generation, patient derived tumor models for precision cancer therapy and drug development. TumorGenesis Inc., formed during the

first

quarter, is presented as part of the condensed consolidated financial statements.

The accompanying condensed consolidated financial statements (the “financial statements”) have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of

$56,525,066.

The Company had cash and cash equivalents of

$2,232,803

as of

March 31, 2018

and needs to raise significant additional capital to meet its operating needs, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

March 31, 2018,

the Company has raised approximately

$35,840,380

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock, (

)

$2,755,000

from a firm commitment underwritten public offering, and (

)

$5,685,000

in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”

Interim Financial Statements

The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the standard on

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January 1, 2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018.

See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

). The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do

not

result in consolidation and are

not

accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The standard is effective for fiscal years beginning after

December 15, 2017,

including interim periods within those fiscal years. As of

March 31, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after

December 15, 2018.

Early adoption is permitted. The Company is currently evaluating the timing of our adoption and the impact that the updated standard will have on the Company’s financial statements.

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

(Tax Reform Act) was signed into law making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry-forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduces the U.S. corporate income tax rates from

34%

21%.

As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate.

The Company reviewed all other significant newly issued accounting pronouncements and determined they are either

not

applicable to its business or that

material effect is expected on its financial position and results of operations.

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made.

Accounting Policies and Estimates

The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$4,394

in the

three

months ended

March 31, 2018

and were

$4,271

in the

three

months ended

March 31, 2017.

Research and Development

Research and development costs are charged to operations as incurred. Research and development expenses were

$94,011

in the

three

months ended

March 31, 2018

and

$84,472

in the

three

months ended

March 31, 2017.

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s

Accounting Standards Codification

(ASC)

820,

fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	March 31, 2018		December 31, 2017

Finished goods	$	32,967	$	62,932
Raw materials		183,216		141,028
Work-In-Process		56,373		61,085
Total	$	272,556	$	265,045

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s investment in fixed assets consists of the following:

	March 31, 2018		December 31, 2017
Computers and office equipment	$	190,484	$	183,528
Leasehold improvements		41,397		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		53,439		43,368
Total		394,275		361,486
Less: Accumulated depreciation		288,266		273,770
Total Fixed Assets, Net	$	106,009	$	87,716

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.

Depreciation expense was

$14,496

in the

three

months ended

March 31, 2018,

and was

$15,685

for the

three

months ended

March 31, 2017.

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$3,671

in the

three

months ended

March 31, 2018,

and was

$2,888

in the

three

months ended

March 31, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The PCT allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

countries of the PCT, including the United States. Filing this single “international” patent application through the PCT is easier and more cost effective than filing separate applications directly with each national or regional patent office in which patent protection is desired.

The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

the Company filed an international (PCT) patent application for its fluid waste collection system and received a favorable determination by the International Searching Authority finding that all of the claims satisfy the requirements for novelty, inventive step and industrial applicability. The Company anticipates that the favorable International Search Report will result in allowance of its various national applications.

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651,

and has sent a Notice of Intent to Grant. The Company is now in the process of identifying the key European countries that it will validate the patent in.

Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any

one

financial institution. The Company has a credit risk concentration because of depositing

$1,984,163

of funds in excess of insurance limits in a single bank.

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

months ended

March 31, 2018

and

2017

were located at or derived from operations in the United States. There was

$26,662

in revenues from sales outside of the United States during

2017

predominantly from the sale of the Company’s

first

System in Canada during

March 2017.

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 - Revenue Recognition	3 Months Ended
Note 2 - Revenue Recognition	Mar. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 2 – REVENUE RECOGNITION Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, at its discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. The Company’s standard payment terms for its customers are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. Customers may also purchase a maintenance plan from the Company, which requires the Company to service the STREAMWAY System for a period of one year subsequent to the one year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one -year period) as maintenance services are provided. A time-elapsed output method is used to measure progress because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not contain any features that create variability in the amount or timing of revenue to be earned. Warranty The Company generally provides one -year warranties against defects in materials and workmanship and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2018, and December 31, 2017, accounts receivable totaled $241,764 and $137,499, respectively. For the three months ended March 31, 2018, the Company did not incur material impairment losses with respect to its receivables. The Company deferred revenues related primarily to maintenance plans of $38,856 and $6,663 as of March 31, 2018 and December 31, 2017, respectively. Practical Expedients The Company has elected the practical expedient not to determine whether contracts with customers contain significant financing components.

Note 3 - Stockholders' Equity, Stock Options and Warrants

3 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

NOTE

– STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

2015

Public Offering of Units

August 31, 2015 (

the “Issuance Date”), the Company completed a public offering (the “Offering”) of

1,666,667

Units (the “Units”) as described below. The public offering price in the Offering was

$9.00

per Unit, and the purchase price for the underwriter of the Offering (the “Underwriter”) was

$8.28

per Unit, resulting in an underwriting discount and commission of

$0.72

(or

8.00%

) per Unit and total net proceeds to the Company before expenses of

$13.8

million. The Company had granted the Underwriter an option for a period of

days to purchase up to an additional

250,000

Units solely to cover over-allotments. The Underwriter chose

not

to purchase any additional Units under the over-allotment option. The Company paid to the Underwriter a non-accountable expense allowance equal to

of the gross proceeds of the Offering and agreed to reimburse expenses incurred by the Underwriter up to

$70,000.

August 31, 2015,

because of the consummation of the Offering and the issuance of the

228,343

Exchange Units in the Unit Exchange described below, the Company issued a total of

1,895,010

Units, comprised of a total of aggregate of

75,801

shares of common stock,

1,895,010

shares of Series B Preferred Stock and

7,580,040

Series A Warrants.

Each Unit consisted of

one

share of common stock, par value

$0.01

per share (the “Common Stock”),

one

share of Series B Convertible Preferred Stock (“Series B Preferred Stock”) and

four

Series A Warrants. The shares of common stock, the shares of Series B Preferred Stock and the Series A Warrants that comprise the Units automatically separated on

February

29,

2016.

For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below.

Series A Warrants

. The Series A Warrants separated from the Series B Convertible Preferred Stock and the Common Stock included within the Units as described above and are currently exercisable. The Series A Warrants terminate on

August 31, 2020.

Each Series A Warrant is exercisable into

one

share of common stock at an initial cash exercise price of

$123.75

per share. The cash exercise price and number of shares of common stock issuable upon cash exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price.

Holders

may

exercise Series A Warrants by paying the exercise price in cash or, in lieu of payment of the exercise price in cash, by electing to receive a number of shares of Common Stock equal to the Black-Scholes Value based upon the number of shares the holder elects to exercise. The number of shares of Common Stock to be delivered will be determined according to the following formula, referred to as the “Cashless Exercise.”

Total Shares = (A

B) / C

Where:

	·	Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise.

	·	A is the total number of shares with respect to which the Series A Warrant is then being exercised.

B is the Black-Scholes Value.

C is the closing bid price of the Common Stock as of

two

trading days prior to the time of such exercise, provided that in

event

may

“C” be less than

$0.43

per share (subject to appropriate adjustment in the event of stock dividends, stock splits or similar events affecting the Common Stock).

The Black-Scholes Value as of

September 30, 2016

was

$4.319,

and the closing bid price of Common Stock as of

September 30, 2016,

was

$4.125.

Therefore, an exercise on that date would have resulted in the issuance of

shares of Common Stock for each Series A Warrant. Approximately

6,141,115

Series A Warrants have been exercised in cashless exercises as of

September 30, 2016,

resulting in the issuance of

2,318,663

shares of Common Stock. If all of the remaining

35,084

Series A Warrants that were issued as part of the Units sold in the Offering and part of the Units issued on

August 31, 2015

were exercised pursuant to a cashless exercise and the closing bid price of the Company’s common stock as of the

two

trading days prior to the time of such exercise was

$0.43

per share or less and the Black-Scholes Value were

$4.319

(the Black-Scholes Value as of

September 30, 2016),

then a total of an additional approximately

564

shares of the Company’s common stock would be issued to the holders of such Series A Warrants.

The Series A Warrants will

not

be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of

4.99%

of the common stock of the Company, determined in accordance with Section

(d) of the Securities Exchange Act of

1934,

as amended, and the regulations promulgated thereunder.

In addition to (but

not

duplicative of) the adjustments to the exercise price and the number of shares of common stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the

three

year anniversary of the Issuance Date, (

) declares or makes any dividend or other distribution of its assets (or rights to acquire its assets) to all or substantially all of the holders of shares of Common Stock at any time after the Issuance Date, or (

) grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of shares of Common Stock. Further, if at any time a Series A Warrant is outstanding, the Company consummates any fundamental transaction, as described in the Series A Warrants and generally including any consolidation or merger into another corporation, or the sale of all or substantially all of the Company’s assets, or other transaction in which the Common Stock is converted into or exchanged for other securities or other consideration, the holder of any Series A Warrants will thereafter receive, the securities or other consideration to which a holder or the number of shares of Common Stock then deliverable upon the exercise or exchange of such Series A Warrants would have been entitled upon such consolidation or merger or other transaction.

Unit Purchase Option.

The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of

August 31, 2015 (

the “Unit Purchase Option”), pursuant to which the Company granted the Underwriter the right to purchase from the Company up to a number of Units equal to

of the Units sold in the Offering (or up to

83,333

Units) or the component securities of such Units at an exercise price equal to

125%

of the public offering price of the Units in the Offering, or

$11.25

per Unit.

Series B Preferred Stock.

Each share of Series B Preferred Stock became convertible into

one

share of Common Stock (subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events) on the

six

-month anniversary of the Issuance Date or on the date of an Early Separation. In addition, the Series B Preferred Stock will automatically convert into shares of common stock upon the occurrence of a fundamental transaction, as described in the certificate of designations for the Series B Preferred Stock but including mergers, sales of the company’s assets, changes in control and similar transactions. The Series B Preferred Stock is

not

convertible by the holder of such preferred stock to the extent (and only to the extent that the holder or any of its affiliates would beneficially own in excess of

4.99%

of the common stock of the Company. The Series B Preferred Stock has

voting rights, except for the right to approve certain amendments to the certificate of designations or similar actions. With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Company, the Series B Preferred Stock shall rank equal to the common stock of the Company.

sinking fund has been established for the retirement or redemption of the Series B Preferred Stock.

Unit Exchange.

February 4, 2014,

the Company raised

$2,055,000

in gross proceeds from a private placement of

20,550

shares of Series A Convertible Preferred Stock, par value

$0.01,

with a stated value of

$100

per share (the “Series A Preferred Shares”) and warrants to purchase shares of the Company’s common stock. The Series A Preferred Shares and warrants were sold to investors pursuant to a Securities Purchase Agreement, dated as of

February 4, 2014.

August 31, 2015,

the Company issued a total of

228,343

Units (the “Exchange Units”) in exchange for the outstanding Series A Preferred Stock which were then cancelled pursuant to an agreement with the holders of the Series A Preferred Shares. The warrants that were issued in connection with the issuance of the Series A Preferred Shares remained outstanding; however, the warrant amounts were reduced so that the warrants are exercisable into an aggregate of

3,991

shares of the Company’s common stock. The Exchange Units were exempt from registration under Section

(a)(

) of the Securities Act. On

August 31, 2015,

the Company filed a termination certificate with the Delaware Secretary of State. Following that date there were

shares of Series A Preferred Stock outstanding, and the previously authorized shares of Series A Preferred Stock resumed the status of authorized but unissued and undesignated shares of preferred stock of the Company.

Redemption of Convertible Notes.

In connection with the closing of the Offering,

$933,074

aggregate principal amount of Convertible Notes plus interest and a

40%

redeemable premium were redeemed for total payments of

$1,548,792.

See Note

Of this amount, approximately

$167,031

was paid to its affiliates in redemption of their Convertible Notes.

Registered Exchange Offer for Warrants.

March 25, 2016,

the Company commenced a registered exchange offer (the “Exchange Offer”) to exchange Series B Warrants (the “Series B Warrants”) to purchase shares of the Company’s common stock, par value

$0.01

per share (the “Warrant Shares”), for up to an aggregate of

3,157,186

outstanding Series A Warrants (the “Series A Warrants”). On

March 31, 2016,

each Series A Warrant could be exercised on a cashless basis for

10.05

shares of common stock. Each Series B Warrant

may

be exercised on a cashless basis for

one

share of common stock. For each outstanding Series A Warrant tendered by holders, the Company offered to issue

10.2

Series B Warrants, which are subject to cashless exercise at a fixed rate of

one

share of common stock per Series B Warrant (subject to further adjustment for stock splits, etc.). The Exchange Offer expired at midnight, Eastern time, on

April 21, 2016.

1,770,556

Series A Warrants were tendered by holders. The Company delivered an aggregate of

18,059,671

Series B Warrants pursuant to the terms of the Exchange Offer. In addition, between

March 31, 2016

and

July 6, 2016

1,251,510

Series A Warrants were exercised in cashless exercises, resulting in the issuance of

20,122

shares of common stock.

2016

Registered Direct Offering

November 29, 2016,

the Company closed a registered direct offering for gross proceeds of

$1,983,337.

The offering consisted of

756,999

shares of common stock priced at

$2.62

per share and

five

-year warrants for

756,999

shares of common stock that become exercisable in

six

months, with a strike price of

$4.46

per share. The net proceeds from the sale of securities, after deducting placement agent fees and related offering expenses, was

$1,739,770.

2017

Private Placement

November 30, 2017,

the Company closed a private placement of a newly created series of preferred stock designated as “Series C Convertible Preferred Stock” with a New York based Family Office. Pursuant to the Securities Purchase Agreement, the investor purchased

1,213,819

shares of Series C stock at a purchase price of

$1.071

per Series C Share, together with a warrant to purchase up to

606,910

shares of common stock. The warrant has an exercise price of

$1.26

per share, subject to adjustment, has a

five

and

one

-half year term and is exercisable commencing

six

months following the date of issuance. Total gross proceeds to the Company were

$1,300,000

before deducting expenses and will be used for general working capital. In connection with the Offering and pursuant to a registration rights agreement, the Company has agreed to file a “resale” registration statement covering all of the shares of common stock issuable upon conversion of the warrant. Pursuant to the Securities Purchase agreement, and as of this filing date, all the Preferred Series C shares were converted at a conversion rate of

1.167

to a maximum of

1,250,269

shares of common stock. The remaining

142,466

shares of Preferred Series C stock were cancelled with a redemption payment to the holder for

$189,285.

2018

Firm Commitment Public Offering

January 2018,

the Company completed a firm commitment underwritten public offering of

2,900,000

Units at an offering price of

$0.95

per Unit, with each Unit consisting of

one

share of the Company’s common stock and

0.3

of a Series E Warrant, with each whole Series E Warrant purchasing

one

share of common stock at an exercise price of

$1.00

per whole share. The shares of Common Stock and Series E Warrants were immediately separable and were issued separately. Gross proceeds were approximately

$2,755,000,

before deducting expenses. The Company granted the underwriter a

-day option to purchase an additional (i) up to

290,000

additional shares of Common Stock at the public offering price per Unit less the price of the Series E Warrant included in the Units and less the underwriting discount and/or (ii) additional Series E Warrants to purchase up to

87,000

additional shares of common stock at a purchase price of

$0.001

per Series E Warrant to cover over-allotments, if any. On

February 21, 2018,

the underwriter exercised on

215,247

shares of common stock, par value

$0.01,

$0.9497

per share as described in the Underwriting Agreement. The Company received net proceeds of

$188,066

after deductions of

$16,354

representing the Underwriter’s discount of

of the purchase price of the shares.

Share Exchange Agreement With Helomics

January 11, 2018,

the Company entered into a share exchange agreement with Helomics Holding Corporation. Pursuant to the share exchange agreement Helomics issued

2,500,000

shares of its Series A Preferred Stock in exchange for

1,100,000

shares of common stock. Under the share exchange agreement, in

March 2018

the Company converted

$500,000

in secured notes into another

of Helomics’ outstanding shares, which results in the Company owning

25%

of Helomics outstanding stock. The secured notes are related to the Company’s previous loans of

$500,000

to Helomics. The

1,100,000

shares are being held in escrow by Corporate Stock Transfer, Inc. as escrow agent. While the Precision Therapeutic shares are held in escrow, they will be voted as directed by the Company’s board of directors and management. The Precision Therapeutic shares will be released to Helomics following a determination that Helomics’ revenues in any

-month period have been equal or greater than

$8,000,000.

The Helomics Preferred Stock issued to the Company is convertible into an aggregate of

20%

of the outstanding capital stock of Helomics. In addition, the terms of the Helomics Preferred Stock include certain protective provisions that require consent of the Company before Helomics

may

take certain actions, including issuing preferred stock senior to the Helomics Preferred Stock or entering into fundamental corporate transactions. The Company also has certain anti-dilution protections and the right to receive dividends.

Increases in Authorized Shares

At a special meeting of the stockholders on

January 29, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

8,000,000

shares to

24,000,000

shares of common stock under the Company’s certificate of incorporation.

At the annual meeting on

December 28, 2017,

the stockholders approved a proposal to increase the number of authorized shares of common stock from

24,000,000

50,000,000

shares of common stock,

$0.01

par value. The amendment to the certificate of incorporation to affect this increase was filed on

January 2, 2018.

Equity Incentive Plan

The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to

three

years. Options under this plan have terms ranging from

three

ten

years.

Accounting for share-based payment

The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.

Since the Company's common stock has

significant public trading history, and the Company has experienced

significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of

years of

small-cap medical companies traded on major exchanges and

mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.

Since the Company has limited trading history in its stock and

first

-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future.

Valuation and accounting for options and warrants

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.

January 15, 2018,

the Company issued inducement stock options in accordance with NASDAQ listing rule for

50,000

shares of common stock, par value

$0.01

$0.97

per share to the Company’s newly hired International Vice President of Sales. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

March 12, 2018,

the Company issued inducement stock options in accordance with NASDAQ rule for

111,112

shares of common stock, par value

$0.01

$1.35

per share to the Company’s newly hired Vice President of Sales and Marketing. The options will vest in

four

equal increments: on the first, second,

third

and

fourth

quarters of the hiring date anniversary.

For grants of stock option and warrants in

2018

the Company used

2.33%

2.87%

risk free interest rate,

dividend rate,

59%

66%

volatility and estimated terms of

years. Value computed using these assumptions ranged from

$0.4816

$1.0044

per share.

The following summarizes transactions for stock options and warrants for the periods indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		325,595			1.11		957,000			1.00
Expired		-			-		(9,580	)		180.12
Exercised		-			-		(38,625	)		1.00

Outstanding at March 31, 2018		3,090,578		$	1.89		2,860,052		$	5.61

March 31, 2018,

1,957,291

stock options are fully vested and currently exercisable with a weighted average exercise price of

$2.18

and a weighted average remaining term of

9.23

years. There are

2,860,052

warrants that are fully vested and exercisable. Stock-based compensation recognized for the

three

months ended

March 2018

and

March 2017

was

$226,387

and

$99,307,

respectively. The Company has

$1,180,348

of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over the next

months.

The following summarizes the status of options and warrants outstanding at

March 31, 2018:

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.97		191,753		9.77
$	1.01		124,358		9.76
$	1.10		22,730		10.00
$	1.35		111,112		9.96
$	1.454		17,200		9.51
$	1.47		2,456,226		9.24
$	2.10		14,286		9.01
$	2.25		293		8.41
$	2.42		24,768		8.39
$	2.80		57,145		8.76
$	3.75		44,000		8.26
$	4.125		3,636		8.51
$	4.1975		7,147		8.47
$	4.25		3,529		8.01
$	5.125		3,902		8.44
$	65.75		190		7.56
$	73.50		1,157		7.76
$	77.50		2,323		7.25
$	80.25		187		7.51
$	86.25		232		7.01
$	131.25		81		4.44
$	148.125		928		4.97
$	150.00		1,760		4.38
$	162.50		123		6.76
$	206.25		121		6.51
$	248.4375		121		5.29
$	262.50		130		5.29
$	281.25		529		4.80
$	318.75		3		5.11
$	346.875		72		6.01
$	431.25		306		5.94
$	506.25		188		5.76
$	596.25		42		5.50

			3,090,578

Warrants
$	1.00		1,675,374		4.39
$	1.07		697,946		4.60
$	2.25		385,000		3.82
$	123.75		94,084		2.42
$	243.75		2,529		1.35
$	309.375		2,850		1.36
$	309.50		222		1.61
$	337.50		178		0.22
$	371.25		946		0.16
$	506.25		59		0.88
$	609.375		862		0.85
			2,860,052

At the annual meeting on

December 28, 2017,

the stockholders approved an amendment to the Company’s

2012

Plan to (i) increase the reserve of shares of Common Stock authorized for issuance thereunder to

5,000,000,

(ii) increase certain threshold limits for grants, and (iii) to re-approve the performance goals thereunder. As described in the Company’s definitive proxy statement filed with the SEC on

December 4, 2017,

amendments to the

2012

Plan were considered at the

2016

annual meeting on

July 28, 2016

but were

not

approved by the required vote. For options to purchase approximately

2.5

million shares granted after the

2016

annual meeting, the grantees agreed

not

to exercise the options prior to further stockholder approval of an increase in the reserve under the

2012

Plan. As a result of the stockholder approval of the amendments at the

2017

annual meeting, these restrictions on exercise were removed on

December 28, 2017.

Due to the removal of this restriction on exercise, the Company recognized a non-cash charge for compensation expense of approximately

$1.9

million in the

fourth

quarter of

2017.

Stock Options and Warrants Granted by the Company

The following table is the listing of stock options and warrants as of

March 31, 2018

by year of grant:

Stock Options:
Year	Shares		Price
2011		173		$281.25
2012		1,841	131.25	–	150.00
2013		1,553	148.125	–	596.25
2014		836	162.50	–	431.25
2015		4,088	65.75	–	86.25
2016		144,422	2.25	–	5.13
2017		2,612,070	1.01	–	2.10
2018		325,595	0.97	–	1.35
Total		3,090,578	$0.97	–	596.25

Warrants:
Year	Shares		Price
2013		1,126	337.50	–	371.25
2014		6,455	243.75	–	609.38
2015		94,151	0.00	–	243.75
2016		756,999		4.46
2017		1,082,946	1.07	–	2.25
2018		918,375		1.00
Total		2,860,052	$0.00	–	609.38

Note 4 - Notes Receivable	3 Months Ended
Note 4 - Notes Receivable	Mar. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 4 – NOTES RECEIVABLE In July 2017, the Company began to advance funds to CytoBioscience for working capital for CytoBioscience’s business. All the notes receivable bear simple interest at 8% and were due in full on December 31, 2017. All the notes are covered by a security interest in all of CytoBioscience’s accounts receivable and related rights in connection with all of the advances. The principal amount of the secured promissory notes receivable from CytoBioscience totaled $1,070,000 as of December 31, 2017. In March 2018, the Company executed a new note replacing all previous CytoBioscience notes for $1,112,524, plus interest paid monthly at the per annum rate of eight percent ( 8% ) on the principal amount. The secured note has a term of two years with the unpaid principal and unpaid accrued interest due and payable on February 28, 2020. In October 2017, the Company advanced $600,000 for working capital for Helomics’ business. The notes receivable bear simple interest at 8% and is due in full on April 30, 2018. Additionally, in December 2017, the Company advanced $67,512.10 to De Lage Landen as fifty percent ( 50% ) down payment for a lease to purchase certain equipment. The note is covered by a security interest in certain equipment of Helomics. In March 2018, the Company converted $500,000 of the note receivable into 833,333 shares of common stock for an additional 5% interest in Helomics Corporation. The Company now has an equity stake in Helomics totaling 25%. The Company is currently negotiating terms for payment on the remaining $167,512.10 plus interest.

Note 5 - Loss Per Share

3 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

– LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Three Months Ended March 31,
	2018			2017
Numerator:
Net loss available in basic and diluted calculation	$	(1,760,022	)	$	(1,341,847	)
Other comprehensive income:
Unrealized gain from marketable securities		-			-
Comprehensive (loss)		(1,760,022	)		(1,341,847	)
Denominator:
Weighted average common shares outstanding-basic		11,383,217			6,450,967

Effect of diluted stock options, warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic		11,383,217			6,450,967

Loss per common share-basic and diluted	$	(0.15	)	$	(0.21	)

(

) The number of shares underlying options and warrants outstanding as of

March 31, 2018

and

March 31, 2017

are

5,950,630

and

1,427,558

respectively. The number of shares underlying the preferred stock as of

March 31, 2018

79,246.

The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes

3 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE

– INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Tax Reform Act was enacted

December 22, 2017.

Effective

January 1, 2018,

the Tax Reform Act reduced corporate income tax rates from

34%

21%.

Other changes effect operating loss carry-forwards and carrybacks, as well as a repeal of the corporate alternative minimum tax. As a result of the Tax Reform Act, deferred tax assets and liabilities were re-measured to account for the lower tax rates. There was

income tax impact from the re-measurement due to the

100%

valuation allowance on the Company’s deferred tax assets.

There is

federal or state income tax provision in the accompanying statements of operations due to the cumulative operating losses incurred and

100%

valuation allowance for the deferred tax assets.

During

September 2013,

the Company experienced an "ownership change" as defined in Section

382

of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The Company

may

have experienced additional “ownership change(s)” since

September 2013,

but a formal study has

not

yet been performed. The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

December 31, 2017,

the Company had approximately

$34.5

million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in

2018,

subject to the Section

382

limitation described above. The federal NOLs will expire beginning in

2022

if unused. The Company also had approximately

$12.2

million of gross NOLs to reduce future state taxable income at

December 31, 2017.

The state NOL’s will expire beginning in

2017

if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At

December 31, 2017,

the federal and state valuation allowances were

$7.4

million and

$0.2

million, respectively.

March 31, 2018,

the Company had approximately

$36.1

million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in

2018,

subject to the Section

382

limitation described above. The federal NOLs will expire beginning in

2022

if unused. The Company also had approximately

$12.4

million of gross NOLs to reduce future state taxable income at

March 31, 2018.

The state NOL’s will expire beginning in

2017

if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At

March 31, 2018,

the federal and state valuation allowances were

$7.7

million and

$1.0

million, respectively.

The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change.

The components of deferred income taxes at

March 31, 2018

and

December 31, 2017

are as follows:

	March 31, 2018		December 31, 2017

Deferred Tax Asset:
Net Operating Loss	$	8,554,404	$	7,393,000
Other		192,522		215,843
Total Deferred Tax Asset		8,746,926		7,608,943
Less Valuation Allowance		8,746,926		7,608,943
Net Deferred Income Taxes	$	—	$	—

Note 7 - Rent Obligation

3 Months Ended

Mar. 31, 2018

Notes to Financial Statements

Leases of Lessee Disclosure [Text Block]

NOTE

– RENT OBLIGATION

November 22, 2017,

the Company signed a

second

amendment to its lease last amended on

January 28, 2013.

The lease as amended has a

three

-year term effective

February 1, 2018

ending

January 31, 2021.

The Company leases

5,773

square feet at this location, of which

2,945

square feet is used for office space and

2,828

is used for manufacturing. The Company lease is effective through

January 31, 2021.

It is expected that this space will be adequate for the Company’s current office and manufacturing needs. Rent expense was

$17,244

and

$16,895

for the

three

months ended

March 31, 2018

and

March 31, 2017,

respectively.

The Company’s rent obligation for the next

four

years is as follows:

2018	$	29,250
2019	$	40,000
2020	$	42,000
2021	$	3,000

Note 8 - Related Party Transactions	3 Months Ended
Note 8 - Related Party Transactions	Mar. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. In April 2018, one of the Company’s directors, Richard L. Gabriel, has executed a six -month consulting contract to help guide operations for the Company’s wholly owned subsidiary TumorGenesis. Under the terms of the agreement Mr. Gabriel will receive $12,000 monthly cash payment. In addition, Mr. Gabriel will receive a grant of 240,000 performance-based restricted stock units (“RSU’s”) under the Company’s Amended and Restated 2012 Stock Incentive Plan, with the vesting and payment of the RSU’s based on performance milestones as set forth in the agreement. Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, the Company entered into a partnership and exclusive reseller agreement with GLG. Under the terms of the agreement, GLG would develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. The Company agreed to issue an aggregate of 400,000 shares of common stock to GLG in four separate tranches of 100,000 shares of common stock in each tranche. The shares reserved in each tranche would be released after the achievement of certain development milestones designated in the agreement. In addition, the Company would pay a royalty to GLG on the sale of individual tests. Also, on November 1, 2016, the Company announced that it agreed to grant GLG exclusive rights to market and distribute the STREAMWAY System in the U.K. On November 2, 2016, the Company announced that it agreed to grant GLG the same rights in Poland and certain other countries in Central Europe. In April 2017, the partnership and exclusive reseller agreement and the distribution agreements between the Company and GLG were terminated.

Note 9 - Retirement Savings Plan	3 Months Ended
Note 9 - Retirement Savings Plan	Mar. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 – RETIREMENT SAVINGS PLAN The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 (k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2018 and 2017, the Company matched 100% , of the employee’s contribution up to 4% of their earnings. The employer contribution was $11,907 and $9,770 for the three months ended March 31, 2018 and March 31, 2017, respectively.

Note 10 - Subsequent Events	3 Months Ended
Note 10 - Subsequent Events	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 – SUBSEQUENT EVENTS In April 2018, one of the Company’s directors, Richard L. Gabriel, has executed a six -month consulting contract to help guide operations for the Company’s wholly owned subsidiary TumorGenesis. Under the terms of the agreement Mr. Gabriel will receive $12,000 monthly cash payment. In addition, Mr. Gabriel will receive a grant of 240,000 performance-based restricted stock units (“RSU’s”) under the Company’s Amended and Restated 2012 Stock Incentive Plan, with the vesting and payment of the RSU’s based on performance milestones as set forth in the agreement. On April 20, 2018, Precision Therapeutics Inc (“Precision”) entered into a letter of intent with Helomics Holding Corporation (“Helomics”) pursuant to which a newly formed subsidiary of Precision would merge with and into Helomic’s (the “Merger”) and Helomics would become the Company’s wholly owned subsidiary. On the effective date of the proposed Merger, Precision would issue to Helomics’ stockholders 7.5 million shares of Precision common stock. In addition, the 1.1 million shares of Precision common stock issued in connection with the share exchange for 20% of Helomics’ capital stock in January 2018 would be released, subject to retention of certain shares in escrow in connection with certain indemnification obligations under the merger agreement. Existing warrants to purchase Helomics’ common stock would be converted into warrants to purchase shares of Precision common stock. The letter of intent is non-binding except for certain enumerated provisions. Completion of the Merger is subject to confirmatory due diligence and negotiation and execution of a definitive merger agreement. There will be certain conditions to closing, including approval of the Merger by the boards of directors and stockholders of Precision and Helomics, the receipt of all necessary approvals and consents of governmental bodies, lenders, lessors and third parties, no material adverse changes in the business of Helomics prior to the closing, no pending or threatened litigation regarding the Merger, conversion of all convertible debt and preferred stock of Helomics into the right to receive the Merger consideration, and other customary conditions.

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Nature of Operations and Continuance of Operations

Precision Therapeutics Inc., (the “Company”) was originally incorporated on

April 23, 2002

in Minnesota as BioDrain Medical, Inc. Effective

August 6, 2013,

the Company changed its name to Skyline Medical Inc. Pursuant to an Agreement and Plan of Merger effective

December 16, 2013,

the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware corporation as the surviving corporation of the merger. On

August 31, 2015,

the Company completed a successful offering and concurrent uplisting to the NASDAQ Capital Market. On

February 1, 2018,

February 1, 2018.

Because of this change, the Company’s common stock trades under the new ticker symbol “AIPT,” effective

February 2, 2018.

Skyline Medical (“Skyline”) remains as an incorporated division of Precision Therapeutics Inc.

As of

March 31, 2018,

the Company had

11,804,073

shares of common stock outstanding, par value

$.01

April 2009,

the Company received

510

(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY System products. The Company has acquired

25%

first

quarter, is presented as part of the condensed consolidated financial statements.

$56,525,066.

The Company had cash and cash equivalents of

$2,232,803

as of

March 31, 2018

not

include any adjustments that might result from the outcome of this uncertainty.

Since inception to

March 31, 2018,

the Company has raised approximately

$35,840,380

in equity offerings, inclusive of (

)

$2,055,000

from a private placement of Series A Convertible Preferred Stock, (

)

$13,555,003

from the public offering of Units, (

)

$1,739,770

from a registered direct offering, (

)

$3,937,500

plus an overallotment of

$358,312

from a firm commitment underwritten public offering, (

)

$1,300,000

from a private placement of Series C Convertible Preferred Stock, (

)

$2,755,000

from a firm commitment underwritten public offering, and (

)

$5,685,000

in debt financing. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources.”

Interim Financial Statements, Policy [Policy Text Block]

Interim Financial Statements

-K filed with the SEC on

April 2, 2018.

The nature of the Company’s business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Developments

May 2014,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

January 1, 2018

using the modified retrospective method applied to those contracts which were

not

completed as of

December 31, 2017.

Results for reporting periods beginning after

January 1, 2018

are presented under Topic

606,

while prior-period amounts have

not

been retrospectively adjusted and continue to be reported in accordance with Topic

605,

Revenue Recognition

. Based upon the Company’s contracts which were

not

completed as of

December 31, 2017,

the Company was

not

required to make an adjustment to the opening balance of retained earnings as of

January 1, 2018.

See Note

for further discussion.

January 2016,

the FASB issued ASU

No.

2016

01,

Financial Instruments-Overall (Subtopic

825

): Recognition and Measurement of Financial Assets and Financial Liabilities

(“ASU

2016

01”

not

result in consolidation and are

not

December 15, 2017,

including interim periods within those fiscal years. As of

March 31, 2018,

there is

material impact on the Company’s financial statements and disclosures.

February 2016,

the FASB issued ASU

No.

2016

02,

“

Leases (Topic

842

)

” (“ASU

2016

02”

December 15, 2018.

Early adoption is permitted. The Company is currently evaluating the timing of our adoption and the impact that the updated standard will have on the Company’s financial statements.

December 22, 2017,

the Tax Cuts and Jobs Act of

2017

34%

21%.

As a result of the enacted law, the Company is required to revalue its deferred tax assets and liabilities at the new enacted rate.

The Company reviewed all other significant newly issued accounting pronouncements and determined they are either

not

applicable to its business or that

material effect is expected on its financial position and results of operations.

Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]

Valuation of Intangible Assets

The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount

may

not

be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount

may

not

be recoverable include, but are

not

Use of Estimates, Policy [Policy Text Block]

Accounting Policies and Estimates

Advertising Costs, Policy [Policy Text Block]

Advertising

Advertising costs are expensed as incurred. Advertising expenses were

$4,394

in the

three

months ended

March 31, 2018

and were

$4,271

in the

three

months ended

March 31, 2017.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. Research and development expenses were

$94,011

in the

three

months ended

March 31, 2018

and

$84,472

in the

three

months ended

March 31, 2017.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

The Company considers all highly liquid debt instruments with a maturity of

three

months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates fair value.

Certificates of Deposit Policy [Policy Text Block]

Certificates of Deposit

Short-term interest-bearing investments are those with maturities of less than

one

year but greater than

three

months when purchased. Certificates with maturity dates beyond

one

year are classified as noncurrent assets. These investments are readily convertible to cash and are stated at cost plus accrued interest, which approximates fair value.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Under generally accepted accounting principles as outlined in the FASB’s

Accounting Standards Codification

(ASC)

820,

820

establishes a

three

-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level

– Observable inputs such as quoted prices in active markets;

Level

– Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level

– Unobservable inputs where there is little or

market data, which requires the reporting entity to develop its own assumptions.

The fair value of the Company’s investment securities was determined based on Level

inputs.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost and net realizable value, with cost determined on a

first

-in,

first

-out basis. Inventory balances are as follows:

	March 31, 2018		December 31, 2017

Finished goods	$	32,967	$	62,932
Raw materials		183,216		141,028
Work-In-Process		56,373		61,085
Total	$	272,556	$	265,045

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

	Years
Computers and office equipment	3	-	7
Leasehold improvements		5
Manufacturing tooling	3	-	7
Demo equipment		3

The Company’s investment in fixed assets consists of the following:

	March 31, 2018		December 31, 2017
Computers and office equipment	$	190,484	$	183,528
Leasehold improvements		41,397		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		53,439		43,368
Total		394,275		361,486
Less: Accumulated depreciation		288,266		273,770
Total Fixed Assets, Net	$	106,009	$	87,716

Depreciation expense was

$14,496

in the

three

months ended

March 31, 2018,

and was

$15,685

for the

three

months ended

March 31, 2017.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was

$3,671

in the

three

months ended

March 31, 2018,

and was

$2,888

in the

three

months ended

March 31, 2017.

The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC

740

Income Taxes

(“ASC

740”

). Under ASC

740,

There is

income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a

100%

valuation allowance for the deferred tax assets and state income taxes is appropriate.

not

that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified

income tax uncertainties.

Tax years subsequent to

2014

remain open to examination by federal and state tax authorities.

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Patents and Intellectual Property

January 25, 2014,

the Company filed a non-provisional Patent Cooperation Treaty (“PCT”) Application

No.

PCT/US2014/013081

claiming priority from the U.S. Provisional Patent Application, number

61756763

which was filed

one

year earlier on

January 25, 2013.

The PCT allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the

148

not

interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.

The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models:

US7469727,

US8123731

and U.S. Publication

No.

US20090216205

(collectively, the “Patents”). These Patents will begin to expire on

August 8, 2023.

July 2015,

The United States Patent Office has assigned application

#14/763,459

to the Company’s previously filed PCT application.

As of

November 22, 2017,

the Company was informed that the European Patent Office has allowed all claims for application

#14743665.3

1651,

and has sent a Notice of Intent to Grant. The Company is now in the process of identifying the key European countries that it will validate the patent in.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Credit Risk

one

financial institution. The Company has a credit risk concentration because of depositing

$1,984,163

of funds in excess of insurance limits in a single bank.

Segment Reporting, Policy [Policy Text Block]

Segments

The Company operates in

two

segments for the sale of its medical device and consumable products. Substantially all the Company’s assets, revenues, and expenses for the

three

months ended

March 31, 2018

and

2017

were located at or derived from operations in the United States. There was

$26,662

in revenues from sales outside of the United States during

2017

predominantly from the sale of the Company’s

first

System in Canada during

March 2017.

Risks and Uncertainties Policy [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the medical device industry, including, but

not

Note 1 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	March 31, 2018		December 31, 2017

Finished goods	$	32,967	$	62,932
Raw materials		183,216		141,028
Work-In-Process		56,373		61,085
Total	$	272,556	$	265,045

Property Plant and Equipment UsefulLife [Table Text Block]

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="; border-collapse: collapse; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td> </td> <td nowrap="nowrap" colspan="3" style="border-bottom: black 1pt solid; text-align: center"><div style="display: inline; font-size: 10pt">Years</div></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Computers and office equipment</div></td> <td> </td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">-</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 84%"><div style="display: inline; font-size: 10pt">Leasehold improvements</div></td> <td style="width: 1%"> </td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">5</div></div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><div style="display: inline; font-size: 10pt">Manufacturing tooling</div></td> <td> </td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">-</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">7</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: white"> <td><div style="display: inline; font-size: 10pt">Demo equipment</div></td> <td> </td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">3</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> </tr> </table></div>

Property, Plant and Equipment [Table Text Block]

	March 31, 2018		December 31, 2017
Computers and office equipment	$	190,484	$	183,528
Leasehold improvements		41,397		25,635
Manufacturing tooling		108,955		108,955
Demo equipment		53,439		43,368
Total		394,275		361,486
Less: Accumulated depreciation		288,266		273,770
Total Fixed Assets, Net	$	106,009	$	87,716

Note 3 - Stockholders' Equity, Stock Options and Warrants (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Share-based Compensation, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding at December 31, 2016		165,643		$	11.22		871,101		$	52.22

Issued		2,612,070			1.45		1,082,946			1.49
Expired		(12,730	)		10.39		(2,790	)		281.46
Exercised		-			-		-			-

Outstanding at December 31, 2017		2,764,983		$	2.00		1,951,257		$	23.74

Issued		325,595			1.11		957,000			1.00
Expired		-			-		(9,580	)		180.12
Exercised		-			-		(38,625	)		1.00

Outstanding at March 31, 2018		3,090,578		$	1.89		2,860,052		$	5.61

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Prices		Shares		Weighted Remaining Life
Options
$	0.97		191,753		9.77
$	1.01		124,358		9.76
$	1.10		22,730		10.00
$	1.35		111,112		9.96
$	1.454		17,200		9.51
$	1.47		2,456,226		9.24
$	2.10		14,286		9.01
$	2.25		293		8.41
$	2.42		24,768		8.39
$	2.80		57,145		8.76
$	3.75		44,000		8.26
$	4.125		3,636		8.51
$	4.1975		7,147		8.47
$	4.25		3,529		8.01
$	5.125		3,902		8.44
$	65.75		190		7.56
$	73.50		1,157		7.76
$	77.50		2,323		7.25
$	80.25		187		7.51
$	86.25		232		7.01
$	131.25		81		4.44
$	148.125		928		4.97
$	150.00		1,760		4.38
$	162.50		123		6.76
$	206.25		121		6.51
$	248.4375		121		5.29
$	262.50		130		5.29
$	281.25		529		4.80
$	318.75		3		5.11
$	346.875		72		6.01
$	431.25		306		5.94
$	506.25		188		5.76
$	596.25		42		5.50

			3,090,578

Warrants
$	1.00		1,675,374		4.39
$	1.07		697,946		4.60
$	2.25		385,000		3.82
$	123.75		94,084		2.42
$	243.75		2,529		1.35
$	309.375		2,850		1.36
$	309.50		222		1.61
$	337.50		178		0.22
$	371.25		946		0.16
$	506.25		59		0.88
$	609.375		862		0.85
			2,860,052

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

Stock Options:
Year	Shares		Price
2011		173		$281.25
2012		1,841	131.25	–	150.00
2013		1,553	148.125	–	596.25
2014		836	162.50	–	431.25
2015		4,088	65.75	–	86.25
2016		144,422	2.25	–	5.13
2017		2,612,070	1.01	–	2.10
2018		325,595	0.97	–	1.35
Total		3,090,578	$0.97	–	596.25

Warrants:
Year	Shares		Price
2013		1,126	337.50	–	371.25
2014		6,455	243.75	–	609.38
2015		94,151	0.00	–	243.75
2016		756,999		4.46
2017		1,082,946	1.07	–	2.25
2018		918,375		1.00
Total		2,860,052	$0.00	–	609.38

Note 5 - Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,
	2018			2017
Numerator:
Net loss available in basic and diluted calculation	$	(1,760,022	)	$	(1,341,847	)
Other comprehensive income:
Unrealized gain from marketable securities		-			-
Comprehensive (loss)		(1,760,022	)		(1,341,847	)
Denominator:
Weighted average common shares outstanding-basic		11,383,217			6,450,967

Effect of diluted stock options, warrants and preferred stock (1)		-			-

Weighted average common shares outstanding-basic		11,383,217			6,450,967

Loss per common share-basic and diluted	$	(0.15	)	$	(0.21	)

Note 6 - Income Taxes (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	March 31, 2018		December 31, 2017

Deferred Tax Asset:
Net Operating Loss	$	8,554,404	$	7,393,000
Other		192,522		215,843
Total Deferred Tax Asset		8,746,926		7,608,943
Less Valuation Allowance		8,746,926		7,608,943
Net Deferred Income Taxes	$	—	$	—

Note 7 - Rent Obligation (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Schedule of Rent Expense [Table Text Block]

2018	$	29,250
2019	$	40,000
2020	$	42,000
2021	$	3,000

Note 1 - Summary of Significant Accounting Policies (Details Textual)			1 Months Ended	3 Months Ended		12 Months Ended		193 Months Ended
	Nov. 29, 2016 USD ($)	Aug. 31, 2015 USD ($)	Jan. 31, 2018 USD ($)	Mar. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2017 USD ($)	Dec. 31, 2018	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Feb. 21, 2018 $ / shares	Dec. 28, 2017 $ / shares	Dec. 31, 2016 USD ($)
Common Stock, Shares, Outstanding, Ending Balance \| shares				11,804,073			6,943,283	11,804,073
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance				$ (56,525,066)			$ (54,765,045)	$ (56,525,066)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				2,232,803	$ 2,086,408		766,189	2,232,803			$ 1,764,090
Stockholders' Equity, Period Increase (Decrease), Total								35,840,380
Stock Issued During Period, Value, New Issues				2,755,087			$ 3,421,188
Proceeds from Issuance or Sale of Equity, Total		$ 13,800,000
Debt Instrument, Increase (Decrease), Net, Total								$ 5,685,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent							34.00%
Advertising Expense				4,394	4,271
Research and Development Expense, Total				94,011	84,472
Depreciation, Total				14,496	15,685
Amortization of Intangible Assets, Total				$ 3,671	$ 2,888
Valuation Allowance Percentage				100.00%				100.00%
Cash, Uninsured Amount				$ 1,984,163				$ 1,984,163
Number of Operating Segments				2
Non-US [Member]
Revenues, Total							$ 26,662
Earliest Tax Year [Member]
Open Tax Year				2014
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent						21.00%
Private Placement [Member]
Stock Issued During Period, Value, New Issues							1,213,819
IPO [Member]
Stock Issued During Period, Value, New Issues								13,555,003
Proceeds from Issuance or Sale of Equity, Total								3,937,500
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs	$ 1,739,770							1,739,770
Proceeds from Issuance or Sale of Equity, Total	$ 1,983,337
Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues				$ 204,422			$ 393,750
Proceeds from Issuance or Sale of Equity, Total								358,312
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total			$ 2,755,000					2,755,000
Series A Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues								2,055,000
Series C Convertible Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues								$ 1,300,000
Helomics Holding Corp. [Member]
Share Exchange Agreement, Potential Interest				25.00%				25.00%

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Finished goods	$ 32,967	$ 62,932
Raw materials	183,216	141,028
Work-In-Process	56,373	61,085
Total	$ 272,556	$ 265,045

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2018
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] \| Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] \| Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant, and Equipment Gross	$ 394,275	$ 361,486
Less: Accumulated depreciation	288,266	273,770
Total Fixed Assets, Net	106,009	87,716
Office Equipment [Member]
Property, Plant, and Equipment Gross	190,484	183,528
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	41,397	25,635
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 53,439	$ 43,368

Note 2 - Revenue Recognition (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, Net, Current, Total	$ 241,764	$ 137,499
Contract with Customer, Liability, Current	$ 38,856	$ 6,663
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 3 - Stockholders' Equity, Stock Options and Warrants (Details Textual)											1 Months Ended	3 Months Ended				9 Months Ended	12 Months Ended		193 Months Ended
	Apr. 01, 2018 USD ($) shares	Mar. 12, 2018 $ / shares shares	Feb. 21, 2018 USD ($) $ / shares shares	Jan. 15, 2018 $ / shares shares	Jan. 11, 2018 USD ($) shares	Nov. 30, 2017 USD ($) $ / shares shares	Nov. 29, 2016 USD ($) $ / shares shares	Mar. 31, 2016 shares	Aug. 31, 2015 USD ($) $ / shares shares	Feb. 04, 2014 USD ($) $ / shares shares	Jan. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2017 USD ($)	Jul. 06, 2016 shares	Sep. 30, 2016 $ / shares shares	Dec. 31, 2018 $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Jan. 02, 2018 shares	Dec. 28, 2017 $ / shares shares	Jan. 29, 2017 shares	Oct. 27, 2016 shares	Apr. 21, 2016 shares	Mar. 25, 2016 $ / shares shares
Shares Issued, Price Per Share \| $ / shares									$ 9
Underwriter Price \| $ / shares									8.28
Underwriting Discount \| $ / shares									$ 0.72
Underwriting Commission									8.00%
Proceeds from Issuance or Sale of Equity, Total \| $									$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units Period									45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted									250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage									1.00%
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.01									$ 0.01	$ 0.01					$ 0.01	$ 0.01		$ 0.01
Share Price \| $ / shares																$ 4.125
Class of Warrant or Right, Outstanding												2,860,052							2,860,052
Stock Issued During Period, Value, New Issues \| $												$ 2,755,087						$ 3,421,188
Common Stock, Shares Authorized												50,000,000	50,000,000					50,000,000	50,000,000		50,000,000	24,000,000	8,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number												1,957,291							1,957,291
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares												$ 2.18							$ 2.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term												9 years 83 days
Class of Warrant or Right Number of Warrants Vested and Exercisable												2,860,052							2,860,052
Allocated Share-based Compensation Expense, Total \| $												$ 226,387		$ 99,307
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $												$ 1,180,348							$ 1,180,348
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost \| $													$ 1,900,000
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares				$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares				$ 0.97
Number of Equal Installments Options are Expected to Vest				4
Vice President of Sales and Marketing [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		111,112
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares		$ 1.35
Number of Equal Installments Options are Expected to Vest		4
Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				5,000,000
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity, Total \| $							$ 1,983,337
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares							$ 4.46
Share Price \| $ / shares							$ 2.62
Stock Issued During Period, Shares, New Issues							756,999
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							756,999
Class of Warrant or Right Term							5 years
Class of Warrant or Right, Vesting Period							180 days
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs \| $							$ 1,739,770												1,739,770
Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 1.26
Stock Issued During Period, Value, New Issues \| $																		$ 1,213,819
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						606,910
Class of Warrant or Right Term						5 years 182 days
Class of Warrant or Right, Vesting Period						180 days
Proceeds from Issuance of Convertible Preferred Stock \| $						$ 1,300,000
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total \| $											$ 2,755,000								$ 2,755,000
Share Price \| $ / shares											$ 0.95
Stock Issued During Period, Shares, New Issues											2,900,000
Over-Allotment Option [Member]
Shares Issued, Price Per Share \| $ / shares			$ 0.9497									$ 0.9497							$ 0.9497
Proceeds from Issuance or Sale of Equity, Total \| $																			$ 358,312
Stock Issued During Period, Value, New Issues \| $												$ 204,422						$ 393,750
Stock Issued During Period, Shares, New Issues			215,247
Sale of Stock, Underwriter Option Term											45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase											290,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase											87,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase \| $ / shares											$ 0.001
Proceeds from Underwriter Shares Exercised, Net \| $			$ 188,066
Stock Issued During Period, Underwriter Discount \| $			$ 16,354
Underwriter Discount Percentage			8.00%
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion												1.167							1.167
Conversion of Stock, Shares Issued												1,250,269
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount \| $									$ 933,074
Debt Instrument Redemption Premium Percentage									40.00%
Debt Instrument Redemption Price \| $									$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates \| $									$ 167,031
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage												4.99%
Stock Issued During Period, Value, New Issues \| $										$ 2,055,000
Stock Issued During Period, Shares, New Issues										20,550
Preferred Stock Par Value \| $ / shares										$ 0.01
Preferred Stock Stated Value \| $ / shares										$ 100
Preferred Stock, Shares Outstanding, Ending Balance												79,246	79,246					79,246	79,246
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance									0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance												0	647,819					647,819	0
Series A Warrants [Member] \| Exchange Offer [Member]
Stock to be Issued for Exchange Offer, Shares, Maximum																									3,157,186
Cashless Exercise of Common Stock Warrants, Total								10.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] \| Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share \| $ / shares																									$ 0.01
Series B Warrants [Member] \| Exchange Offer [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right								1
Class of Warrant or Right Exercised During Period															1,251,510
Stock Issued During Period, Shares, Warrants Exercised															20,122
Cashless Exercise of Common Stock Warrants, Total								10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																								18,059,671
Series E Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares												$ 1							$ 1
Series E Warrants [Member] \| The 2018 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right											1
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares											$ 1
Class of Warrant or Right, Issued per Unit											0.3
Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities												589,747						660,522
Stock Issued During Period, Value, New Issues \| $												$ 29,000						$ 17,500
Stock Issued During Period, Shares, New Issues												2,900,000						1,750,000
Common Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues \| $
Stock Issued During Period, Shares, New Issues
Common Stock [Member] \| Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues \| $												$ 2,153						$ 1,750
Stock Issued During Period, Shares, New Issues												215,247						175,000
Common Stock [Member] \| Series E Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised												55,796
Preferred Stock [Member]
Stock Issued During Period, Value, New Issues \| $
Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Value, New Issues \| $																		12,138
Preferred Stock [Member] \| Over-Allotment Option [Member]
Stock Issued During Period, Value, New Issues \| $
Preferred Stock [Member] \| Series C Convertible Preferred Stock [Member] \| Subsequent Event [Member]
Stock Redeemed or Called During Period, Shares	142,466
Payments for Repurchase of Convertible Preferred Stock \| $	$ 189,285
Preferred Stock [Member] \| Series C Convertible Preferred Stock [Member] \| Private Placement [Member]
Shares Issued, Price Per Share \| $ / shares						$ 1.071
Stock Issued During Period, Shares, New Issues						1,213,819
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit									1
Common Stock, Par or Stated Value Per Share \| $ / shares									$ 0.01
Corporate Stock Transfer Inc. [Member] \| Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right																40
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares												$ 123.75							123.75
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise												2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula \| $ / shares												$ 0.43							$ 0.43
Warrants Option to Settle in Cash Fair Value Disclosure \| $ / shares																$ 4.319
Class of Warrant or Right Exercised During Period																6,141,115
Stock Issued During Period, Shares, Warrants Exercised																2,318,663
Class of Warrant or Right, Outstanding												35,084							35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise \| $ / shares												$ 0.43							$ 0.43
Beneficial Ownership Limitation Percentage												4.99%
Corporate Stock Transfer Inc. [Member] \| Series A Warrants [Member] \| Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period, Shares, Warrants Exercised																564
Corporate Stock Transfer Inc. [Member] \| Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit									1
Corporate Stock Transfer Inc. [Member] \| Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit									4
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues					1,100,000
Share Exchange Agreement, Shares Received					2,500,000
Share Exchange Agreement, Convertible Notes Receivable \| $												$ 500,000							$ 500,000
Share Exchange Agreement, Convertible Notes, Percent of Stock												5.00%							5.00%
Share Exchange Agreement, Potential Interest												25.00%							25.00%
Share Exchange Agreement, Number of Shares Held in Escrow												1,100,000							1,100,000
Share Exchange Agreement, Contingent Revenue, Minimum \| $					$ 8,000,000
Convertible Preferred Stock Held, Conversion Feature, Percent					20.00%
Maximum [Member]
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter \| $									$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares												$ 609.38							$ 609.38
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares												$ 596.25
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate												2.87%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate												66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term												10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares												$ 1.0044
Maximum [Member] \| Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period												3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												10 years
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares												$ 0							$ 0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares												$ 0.97
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate												2.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate												59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term												5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares												$ 0.4816
Minimum [Member] \| Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												3 years
Exchange Units [Member]
Unit Purchase Option Units Sold									1,666,667
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,895,010
Exchange Units [Member] \| Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									3,991
Exchange Units [Member] \| Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									7,580,040
Exchange Units [Member] \| Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									75,801
Exchange Units [Member] \| Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities									1,895,010
Exchange Units [Member] \| Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued									228,343
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage									5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase									83,333
Unit Purchase Option Exercise Price, Percentage									125.00%
Unit Purchase Option Exercise Price \| $ / shares									$ 11.25
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																	325,595	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares																	$ 1.11	$ 1.45
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition												1 year 180 days

Note 3 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Number of Shares Outstanding (in shares)	3,090,578
Warrant [Member]
Number of Shares Outstanding (in shares)	1,951,257	1,951,257	871,101
Average Exercise Price Outstanding (in dollars per share)	$ 23.74	$ 23.74	$ 52.22
Number of Shares Issued (in shares)		957,000	1,082,946
Average Exercise Price Issued (in dollars per share)		$ 1	$ 1.49
Number of Shares Expired (in shares)		(9,580)	(2,790)
Average Exercise Price Expired (in dollars per share)		$ 180.12	$ 281.46
Number of Shares Exercised (in shares)		(38,625)
Average Exercise Price Exercised (in dollars per share)		$ 1
Number of Shares Outstanding (in shares)		2,860,052	1,951,257
Average Exercise Price Outstanding (in dollars per share)		$ 5.61	$ 23.74
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	2,764,983	2,764,983	165,643
Average Exercise Price Outstanding (in dollars per share)	$ 2	$ 2	$ 11.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		325,595	2,612,070
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 1.11	$ 1.45
Number of Shares Expired (in shares)			(12,730)
Average Exercise Price Expired (in dollars per share)			$ 10.39
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)		3,090,578	2,764,983
Average Exercise Price Outstanding (in dollars per share)		$ 1.89	$ 2

Note 3 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Shares, options (in shares)	3,090,578
Shares, warrants (in shares)	2,860,052
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 1
Shares, warrants (in shares)	1,675,374
Weighted average remaining life, warrants (Year)	4 years 142 days
Warrant Two [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 1.07
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	4 years 219 days
Warrant Three [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	3 years 299 days
Warrant Four [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	2 years 153 days
Warrant Five [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	1 year 127 days
Warrant Six [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	1 year 131 days
Warrant Seven [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 309.50
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	1 year 222 days
Warrant Eight [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 337.50
Shares, warrants (in shares)	178
Weighted average remaining life, warrants (Year)	80 days
Warrant Nine [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 371.25
Shares, warrants (in shares)	946
Weighted average remaining life, warrants (Year)	58 days
Warrant Ten [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 506.25
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	321 days
Warrant Eleven [Member]
Exercise price per share (in dollars per share) \| $ / shares	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	310 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 0.97
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	9 years 281 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.01
Shares, options (in shares)	124,358
Weighted average remaining life, options (Year)	9 years 277 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.10
Shares, options (in shares)	22,730
Weighted average remaining life, options (Year)	10 years
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.35
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	9 years 350 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.454
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 1.47
Shares, options (in shares)	2,456,226
Weighted average remaining life, options (Year)	9 years 87 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	9 years 3 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	8 years 149 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.42
Shares, options (in shares)	24,768
Weighted average remaining life, options (Year)	8 years 142 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	8 years 277 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 3.75
Shares, options (in shares)	44,000
Weighted average remaining life, options (Year)	8 years 94 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	8 years 171 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	8 years 160 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 65.75
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	7 years 204 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	4 years 160 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	4 years 354 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	4 years 138 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 186 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 105 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	5 years 105 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	4 years 292 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	5 years 40 days
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	5 years 343 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	5 years 277 days
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share) \| $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	5 years 182 days

Note 3 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Shares, options (in shares) \| shares	3,090,578
Shares, warrants (in shares) \| shares	2,860,052
Minimum [Member]
Price, options (in dollars per share)	$ 0.97
Exercise price per share (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25
Exercise price per share (in dollars per share)	$ 609.38
Warrants 2013 [Member]
Shares, warrants (in shares) \| shares	1,126
Warrants 2013 [Member] \| Minimum [Member]
Exercise price per share (in dollars per share)	$ 337.50
Warrants 2013 [Member] \| Maximum [Member]
Exercise price per share (in dollars per share)	$ 371.25
Warrants 2014 [Member]
Shares, warrants (in shares) \| shares	6,455
Warrants 2014 [Member] \| Minimum [Member]
Exercise price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] \| Maximum [Member]
Exercise price per share (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares) \| shares	94,151
Warrants 2015 [Member] \| Minimum [Member]
Exercise price per share (in dollars per share)	$ 0
Warrants 2015 [Member] \| Maximum [Member]
Exercise price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) \| shares	756,999
Exercise price per share (in dollars per share)	$ 4.46
Warrants 2017 [Member]
Shares, warrants (in shares) \| shares	1,082,946
Warrants 2017 [Member] \| Minimum [Member]
Exercise price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] \| Maximum [Member]
Exercise price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) \| shares	918,375
Exercise price per share (in dollars per share)	$ 1
Stock Options 2011 [Member]
Shares, options (in shares) \| shares	173
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) \| shares	1,841
Stock Options 2012 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) \| shares	1,553
Stock Options 2013 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 148.125
Stock Options 2013 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) \| shares	836
Stock Options 2014 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) \| shares	4,088
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	144,422
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	2,612,070
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	325,595
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0.97
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 1.35

Note 4 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended
Note 4 - Notes Receivable (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Jul. 31, 2017
Advance to Helomics [Member]
Notes Receivable, Interest Rate, Stated Percentage			8.00%
Payments to Acquire Notes Receivable			$ 600,000
Advances to De Lage Landen [Member]
Payments to Acquire Notes Receivable		$ 67,512.10
CytoBioscience [Member] \| Promissory Notes Receivable [Member]
Notes Receivable, Interest Rate, Stated Percentage	8.00%			8.00%
Financing Receivable, Net, Total	$ 1,112,524	$ 1,070,000
Notes Receivable, Term	2 years
Helomics Holding Corp. [Member]
Financing Receivable, Net, Total	$ 167,512.10
Share Exchange Agreement, Outstanding Receivables, Amount Converted	$ 500,000
Share Exchange Agreement, Shares Received Upon Conversion of Receivables	833,333
Share Exchange Agreement, Convertible Notes, Percent of Stock	5.00%
Investment, Ownership Percent	25.00%

Note 5 - Loss Per Share (Details Textual) - shares	3 Months Ended
Note 5 - Loss Per Share (Details Textual) - shares	Mar. 31, 2018	Mar. 31, 2017
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,950,630	1,427,558
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Net loss available in basic and diluted calculation

$ (1,760,022)

$ (1,341,847)

$ (7,746,593)

Unrealized gain from marketable securities

$ (1,501)

Comprehensive (loss)

$ (1,760,022)

$ (1,341,847)

Weighted average common shares outstanding-basic (in shares)

11,383,217

6,450,967

Effect of diluted stock options, warrants and preferred stock (1) (in shares)

^[1]

Loss per common share - basic and diluted (in dollars per share)

$ (0.15)

$ (0.21)

[1]

The number of shares underlying options and warrants outstanding as of March 31, 2018 and March 31, 2017 are 5,950,631 and 1,427,558 respectively. The number of shares underlying the preferred stock as of March 31, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			34.00%
Income Tax Expense (Benefit), Total	$ 0
Valuation Allowance Percentage	100.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 36,100		$ 34,500
Operating Loss Carryforwards, Valuation Allowance, Total	7,700		7,400
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	12,400		12,200
Operating Loss Carryforwards, Valuation Allowance, Total	$ 1,000		$ 200
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Net Operating Loss	$ 8,554,404	$ 7,393,000
Other	192,522	215,843
Total Deferred Tax Asset	8,746,926	7,608,943
Less Valuation Allowance	8,746,926	7,608,943
Net Deferred Income Taxes	$ 0	$ 0

Note 7 - Rent Obligation (Details Textual)	3 Months Ended
Note 7 - Rent Obligation (Details Textual)	Mar. 31, 2018 USD ($) ft²	Mar. 31, 2017 USD ($)
Operating Leases, Rent Expense, Total \| $	$ 17,244	$ 16,895
Corporate Office, Minnesota [Member]
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation	3 years
Area of Real Estate Property	5,773
Corporate Office, Minnesota [Member] \| Office Space [Member]
Area of Real Estate Property	2,945
Corporate Office, Minnesota [Member] \| Manufacturing Facility [Member]
Area of Real Estate Property	2,828

Note 7 - Rent Obligation - Rent Obligation (Details)	Mar. 31, 2018 USD ($)
2018	$ 29,250
2019	40,000
2020	42,000
2021	$ 3,000

Note 8 - Related Party Transactions (Details Textual) - USD ($)		1 Months Ended
	Sep. 20, 2016	Apr. 30, 2018
Director [Member] \| Subsequent Event [Member]
Related Party Transaction, Monthly Cash Payment		$ 12,000
Director [Member] \| Subsequent Event [Member] \| Restricted Stock Units (RSUs) [Member] \| Stock Incentive Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		240,000
GLG Pharma, LLC. [Member]
Stock Expected to be Issued Upon Agreement, Shares	400,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche One	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Four	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Two	100,000
Stock Expected to be Issued Upon Agreement, Shares, Tranche Three	100,000

Note 9 - Retirement Savings Plan (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%		100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%		4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 11,907	$ 9,770

Note 10 - Subsequent Events (Details Textual) - USD ($)			1 Months Ended
Note 10 - Subsequent Events (Details Textual) - USD ($)	Apr. 20, 2018	Jan. 11, 2018	Apr. 30, 2018
Helomics Holding Corp. [Member]
Stock Issued During Period, Shares, New Issues		1,100,000
Convertible Preferred Stock Held, Conversion Feature, Percent		20.00%
Subsequent Event [Member] \| Helomics Holding Corp. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	7,500,000
Director [Member] \| Subsequent Event [Member]
Related Party Transaction, Monthly Cash Payment			$ 12,000
Director [Member] \| Subsequent Event [Member] \| Stock Incentive Plan 2012 [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			240,000